E Motamedian1, E Taheri1, F Bagheri1. 1. Department of Biotechnology, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran.
Abstract
OBJECTIVES: If screening to find effective drugs is possible, the inhibition of proliferation using existing drugs can be a practical strategy to control the drug resistance of cancer. Development of a system-oriented strategy to find effective drugs was the main aim of this research. MATERIALS AND METHODS: An algorithm (transcriptional regulated flux balance analysis [TRFBA]) integrating a generic human metabolic model with transcriptomic data was used to identify genes affecting the growth of drug-resistant cancer cells. Drugs that inhibit activation of the target genes were found and their effect on the proliferation was experimentally evaluated. RESULTS: Experimental assessments demonstrated that TRFBA improves the prediction of cancer cell growth in comparison with previous algorithms. The algorithm was then used to propose the system-oriented strategy to search drugs effective in limiting the growth rate of the cisplatin-resistant A2780 epithelial ovarian cancer cell. Experimental evaluations resulted in the selection of azathioprine, terbinafine, hydralazine and sodium valproate that appropriately inhibit the proliferation of resistant cancer cells while minimally affecting normal cells. Furthermore, experimental data indicate that the selected drugs are synergistic and can be used in combination therapies. CONCLUSIONS: The proposed strategy was successful to identify drugs effective on the viability of resistant cancer cells. This strategy can enhance the potency of treatments for drug-resistant cancer cells and provides the possibility of using existing drugs.
OBJECTIVES: If screening to find effective drugs is possible, the inhibition of proliferation using existing drugs can be a practical strategy to control the drug resistance of cancer. Development of a system-oriented strategy to find effective drugs was the main aim of this research. MATERIALS AND METHODS: An algorithm (transcriptional regulated flux balance analysis [TRFBA]) integrating a generic human metabolic model with transcriptomic data was used to identify genes affecting the growth of drug-resistant cancer cells. Drugs that inhibit activation of the target genes were found and their effect on the proliferation was experimentally evaluated. RESULTS: Experimental assessments demonstrated that TRFBA improves the prediction of cancer cell growth in comparison with previous algorithms. The algorithm was then used to propose the system-oriented strategy to search drugs effective in limiting the growth rate of the cisplatin-resistant A2780 epithelial ovarian cancer cell. Experimental evaluations resulted in the selection of azathioprine, terbinafine, hydralazine and sodium valproate that appropriately inhibit the proliferation of resistant cancer cells while minimally affecting normal cells. Furthermore, experimental data indicate that the selected drugs are synergistic and can be used in combination therapies. CONCLUSIONS: The proposed strategy was successful to identify drugs effective on the viability of resistant cancer cells. This strategy can enhance the potency of treatments for drug-resistant cancer cells and provides the possibility of using existing drugs.
Authors: Mary-Ellen Harper; Andreas Antoniou; Elizabeth Villalobos-Menuey; Alicia Russo; Richard Trauger; Minda Vendemelio; Amanda George; Richard Bartholomew; Dennis Carlo; Azhar Shaikh; Jami Kupperman; Evan W Newell; Ivan A Bespalov; Susan S Wallace; Ye Liu; Jeffrey R Rogers; Gregory L Gibbs; Jack L Leahy; Robert E Camley; Robert Melamede; M Karen Newell Journal: FASEB J Date: 2002-10 Impact factor: 5.191
Authors: David W Chan; Vincent W S Liu; George S W Tsao; Kwok-Ming Yao; Toru Furukawa; Karen K L Chan; Hextan Y S Ngan Journal: Carcinogenesis Date: 2008-07-16 Impact factor: 4.944
Authors: Lucía Trilla-Fuertes; Angelo Gámez-Pozo; Jorge M Arevalillo; Mariana Díaz-Almirón; Guillermo Prado-Vázquez; Andrea Zapater-Moros; Hilario Navarro; Rosa Aras-López; Irene Dapía; Rocío López-Vacas; Paolo Nanni; Sara Llorente-Armijo; Pedro Arias; Alberto M Borobia; Paloma Maín; Jaime Feliú; Enrique Espinosa; Juan Ángel Fresno Vara Journal: Oncotarget Date: 2018-01-08